Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 4;23(1):396.
doi: 10.1186/s12885-023-10861-y.

Functional role and epithelial to mesenchymal transition of the miR-590-3p/MDM2 axis in hepatocellular carcinoma

Affiliations

Functional role and epithelial to mesenchymal transition of the miR-590-3p/MDM2 axis in hepatocellular carcinoma

Alaa Ibrahem Youssef et al. BMC Cancer. .

Abstract

Background: There is considerable evidence that microRNAs (miRNAs) regulate several key tumor-associated genes/pathways and may themselves have a dual regulatory function either as tumor suppressors or oncogenic miRNA, depending on the tumor type. MicroRNA-590-3p (miR-590-3p) is a small non-coding RNA involved in the initiation and progression of numerous tumors. However, its expression pattern and biological role in hepatocellular carcinoma (HCC) are controversial.

Results: In the current work, computational and RT-qPCR analysis revealed that HCC tissues and cell lines exhibited miR-590-3p downregulation. Forced expression of miR-590-3p attenuated HepG2 cells proliferation, migration, and repressed EMT-related gene expression. Bioinformatic, RT-qPCR, and luciferase assays revealed that MDM2 is a direct functional target of miR-590-3p. Moreover, the knockdown of MDM2 mimicked the inhibitory effect of miR-590-3p in HepG2 cells.

Conclusion: We have identified not only novel targets for miR-590-3p in HCC, but also novel target genes for miR590-3p/MDM2 pathway in HCC like SNAIL, SLUG, ZEB1, ZEB2, and N-cadherin. Furthermore, these findings demonstrate a crucial role for MDM2 in the regulatory mechanism of EMT in HCC.

Keywords: Colony formation; MDM2 knockdown; Transwell migration; miR-590-3p; miR-590-3p mimics.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
The downregulation pattern of hsa-miR-590-3p in hepatocellular carcinoma. A miR-590-3p differential expression between HCC (n = 370) relative to the normal liver tissues (n = 50). B MiR-590-3p is significantly lower in the SNU449 cell line compared to HepG2 cells, as shown by RT qPCR results. Data represents the mean ± SEM (N = 3). P-value was depicted using Student’s t-test. (** P < 0.01, **** P < 0.0001)
Fig. 2
Fig. 2
miR-590-3p suppresses cellular clonogenicity, migration and EMT in HepG2 cells. A The transfection efficiency of miR-590-3p mimics compared to negative control B Overexpressing miR-590-3p significantly decreased the number of HepG2 colonies compared to the negative control. C Overexpressing miR-590–3 showed a low but significant reduction in the number of migrated cells as compared to the negative control in the HepG2 cell line. D overexpressing miR-590-3p caused a significant decrease in the mRNA levels of SNAIL, SLUG, ZEB1, and ZEB2. E N-cadherin levels were significantly lower in miR-590-3p mimics transfected cells, while Vimentin levels were not significantly changed. Images were taken at 20X magnification using a fluorescent microscope and counted using Fiji Image J software. Data represents the mean ± SEM. (N = 2 for qPCR, N = 3 for Transwell and colony assay). P-value was depicted using Student’s t test. (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 3
Fig. 3
MDM2 is a novel direct target gene of miR-590-3p in HCC. A Differential expression of MDM2 between normal and HCC tissues as obtained from TCGA data using Pan-cancer analysis platform. B The mRNA levels of MDM2 in HepG2 cells transfected with miR-590-3p in mimic compared to the negative control. C The sequence alignment between MDM2 and miR-590-3p. D Relative luciferase activity of miR-590-3p mimic or negative control on the WT or MUT versions of MDM2. Data represents the mean ± SEM. (N = 3 for qPCR, N = 2 for luciferase assay). P-value was depicted using Student’s t-test. (* P < 0.05, ** P < 0.01, *** P < 0.001)
Fig. 4
Fig. 4
Inhibition of MDM2 mimics the tumor suppressor effect of miR-590-3p. A RT-qPCR showing the expression of MDM2 after transfecting HepG2 cells with si-MDM2 or si-NC. B Western blot showing the successful depletion of MDM2 protein expression. Full-length blot is presented in Supplementary Figure S3(A&B). C Colony formation assay was performed to assess the effect of MDM2 knockdown on the ability of HepG2 cells to form colonies. D Transwell assay was employed to verify the effect of MDM2 silencing on the migration of HepG2 cells. E RT-qPCR showing the expression of SNAIL, SLUG, ZEB1, and ZEB2 following MDM2 knockdown, with GAPDH as an internal control. F RT-qPCR showing the transcript levels of N-cadherin and Vimentin in si-NTC and si-MDM2 transfected HepG2 cells, with GAPDH as an internal control. Data values are expressed as the mean ± SEM (N = 3) for all assays except for western blotting (N = 2). Statistically significant at *P < 0.05, ** P < 0.01, ***P < 0.001 (Student t-test, two-tailed). siMDM2-MDM2 siRNA, siNC- negative siRNA
Fig. 5
Fig. 5
Hypothetical model for miR-590-3p/MDM2 axis role in HCC. MDM2 acts as an oncogene in HCC. miR-590-3p exerts tumor suppressive roles in HCC by directly targeting MDM2. The figure was created with Biorender.com

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Suresh D, Srinivas AN, Kumar DP. Etiology of Hepatocellular Carcinoma: Special Focus on Fatty Liver Disease. Front Oncol. 2020;10:2673. doi: 10.3389/fonc.2020.601710. - DOI - PMC - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primer. 2021;7(1):1–28. - PubMed
    1. Schütte K, Schinner R, Fabritius MP, Möller M, Kuhl C, Iezzi R, et al. Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial. Liver Cancer. 2020;9(6):771–786. doi: 10.1159/000510798. - DOI - PMC - PubMed
    1. Lin YL, Li Y. Study on the hepatocellular carcinoma model with metastasis. Genes Dis. 2020;7(3):336–350. doi: 10.1016/j.gendis.2019.12.008. - DOI - PMC - PubMed

MeSH terms